Assessment of Risk-Adjusted Antithrombotic Strategies and 30-Day Clinical Outcomes Following Endoscopic Treatment for Non-Variceal Upper Gastrointestinal Bleeding: A Retrospective Cohort Analysis

1

The study assessed the impact of adherence to a risk-based antithrombotic management framework on 30-day outcomes after endoscopic treatment for NVUGIB.
2

Adherent patients showed significantly lower rates of rebleeding (5.2%) and net adverse clinical events (12.0%) compared to non-adherent patients (17.8% and 34.0%, respectively).
3

The study included 150 index admissions, with 100 patients documented as adherent and 50 as non-adherent to the management framework.
4

Overall, 9.2% of patients experienced rebleeding, 10.7% had thromboembolism, and 19.3% experienced net adverse clinical events within 30 days.
5

The findings suggest that documented adherence to a structured management framework correlates with fewer adverse events in the short term.

1